LumiraDx on Tuesday reported an 82 percent year-over-year decrease in first quarter revenues due to falling demand for COVID-19 testing.

According to the report of "The Developments and Trends of China's Medical Device Industry" released by Roland Berger, a world leading management consultancy, the Chinese medical device market exceeded 900 billion yuan in 2022. It is projected to exceed 2.2 trillion CNY (about 320 billion USD) by 2030, making China potentially the largest medical device market globally.

CareDx, Inc. (Nasdaq: CDNA) ¨C The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ¨C today reported financial results for the first quarter ended March 31, 2023.

A French team led by investigators at Institut Cochin in Paris has received €1.5 million ($1.7 million) in EU funding to develop biomarkers for endometriosis, a condition where tissue similar to the lining of a woman's uterus grows outside of it.

Leading domestic company for high-end laboratory consumables has received nearly 100 million yuan in funding

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2023.

Revvity, Inc., today reported financial results for the first quarter ended April 2, 2023.

On May 8, Singlera Genomics announced that its self-developed PDACatch test, a novel DNA methylation-based liquid biopsy test for detecting pancreatic cancer in high-risk populations, has been granted Breakthrough Medical Device designation by FDA.

Cue Health Inc., a healthcare technology company, today reported financial results for the first quarter 2023.

Siemens Healthineers AG today announces its results for the second quarter, ending March 31, of fiscal year 2023.

Sansure Biotech announced that the company will invest CNY 90.93 million, accounting for 53.2% of the shares, and jointly establish Hunan Sansure Ansai Biotechnology.

Invitae, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2023.

DiaSorin said that its first quarter 2023 revenues fell 19 percent year over year on a sharp decline in COVID-19 testing, partially offset by growth in its non-COVID-19-related diagnostics revenues.

Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia.

BioM¨¦rieux announced on Tuesday that its BioFire SpotFire Respiratory Panel Mini has obtained CLIA wavier from the US Food and Drug Administration.

The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine¡¯s FoundationOne Liquid CDx as a companion diagnostic for Takeda¡¯s Exkivity (mobocertinib).

Veracyte, Inc. today announced financial results for the first quarter ended March 31, 2023.

On April 25-26, Yin Ye, CEO of BGI Genomics, and his delegation visited Serbia and signed a memorandum of understanding with the Serbian Ministry of Health on cooperation in public health and precision testing.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.

BD, a leading global medical technology company, today announced results for its second quarter of fiscal 2023, which ended March 31, 2023.